Who is sponsoring NCT02007421?

NCT02007421 is sponsored by Kirby Institute.

What condition does NCT02007421 study?

NCT02007421 studies Human Papillomavirus, Cancer.

Is NCT02007421 still recruiting?

NCT02007421 is currently completed. Last updated 2 December 2019.

Last reviewed 2019-12-02 · How we verify

NCT02007421: SPANC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of the Prevention of Anal Cancer

Completed NA Last updated 2 December 2019

What this trial tests

NA trial testing Participants asked questions about recent experiences of anal intercourse in the last six months. in Human Papillomavirus in 617 participants. Completed in 4 December 2018.

Timeline

10 September 2010

Primary endpoint
4 May 2018

4 December 2018

Quick facts

Lead sponsor	Kirby Institute
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	617
Start date	10 September 2010
Primary completion	4 May 2018
Estimated completion	4 December 2018
Sites	2 locations across Australia

Drugs / interventions tested

Participants asked questions about recent experiences of anal intercourse in the last six months.
High Resolution Anoscopy

Conditions studied

Human Papillomavirus — all drugs for Human Papillomavirus →
Cancer — all drugs for Cancer →

Sponsor

Kirby Institute

Who can join

35 and older, male only, with Human Papillomavirus or Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

SPANC stands for Study of the Prevention of Anal Cancer. There are more than 100 types of human papillomavirus (HPV). Some HPV types cause genital warts and other types cause more than 90% of anal cancer. Gay men are over 20 times more likely than others to develop anal cancer. SPANC is a study of anal (HPV) infection and related anal disease in gay men. The study will provide important information to guide the possible future introduction of anal cancer screening programs for gay men.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Screening for Anal Cancer in Women.
Moscicki AB, Darragh TM, Berry-Lawhorn JM, Roberts JM, et al · · 2015 · cited 90× · PMID 26103446 · DOI 10.1097/lgt.0000000000000117
Human papillomavirus 16-specific T-cell responses and spontaneous regression of anal high-grade squamous intraepithelial lesions.
Tong WW, Shepherd K, Garland S, Meagher A, et al · · 2015 · cited 27× · PMID 25139018 · DOI 10.1093/infdis/jiu461
Effect of Human Papillomavirus Vaccine to Interrupt Recurrence of Vulvar and Anal Neoplasia (VIVA): A Trial Protocol.
Stankiewicz Karita HC, Hauge K, Magaret A, Mao C, et al · · 2019 · cited 23× · PMID 30977845 · DOI 10.1001/jamanetworkopen.2019.0819

Verify or expand the search:

Other recruiting trials for Human Papillomavirus

Currently open trials in the same condition.

NCT06519994 — Feasibility of Intravaginal Artesunate as Adjuvant HPV & Cervical Precancer Treatment in Kenya · Phase 2 · active not recruiting
NCT06434337 — Evaluation of a Novel Point-of-Care Diagnostic Test for Human Papillomavirus (HPV) · recruiting
NCT05365048 — Provider Recommendation and HPV Vaccination · NA · recruiting
NCT05026138 — Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune) · recruiting
NCT04708470 — A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, · Phase 1, PHASE2 · active not recruiting

Other Kirby Institute trials

Trials by the same sponsor.

NCT07145736 — Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical · Phase 4 · recruiting
NCT06220370 — PATH Study: People With Injecting Related Infections: Assessing Treatment Outcomes for Those Who Are Hospitalised. · not yet recruiting
NCT05415267 — Immunosuppression and COVID-19 Boosters · Phase 3 · recruiting
NCT05144776 — Evaluation of Hepatitis B Virus (HBV) DNA Test As Point of Care Tool · completed
NCT04014179 — Enhancing Hepatitis C Testing and Treatment Among People Who Inject Drugs Attending Needle and Syringe Programs · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02007421 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kirby Institute
Last refreshed: 2 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02007421.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing